e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Towards new anti-inflammatory and anti-fibrotic agents
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Blood eosinophils in inhaled steroid dose titration
S. Jabbal (Dundee, United Kingdom)
Source:
International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents
Session:
Towards new anti-inflammatory and anti-fibrotic agents
Session type:
Oral Presentation
Number:
4830
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Jabbal (Dundee, United Kingdom). Late Breaking Abstract - Blood eosinophils in inhaled steroid dose titration. 4830
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids.
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma
Source: International Congress 2019 – Powerful cohort studies with/without lung function
Year: 2019
Late Breaking Abstract - Explore the effective dose of bronchodilator nebulization via high flow nasal cannula in adult COPD and asthma patients
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Patterns of inhaled corticosteroid-formoterol prescriptions in Poland
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
LATE-BREAKING ABSTRACT: Blood Eosinophil Count as a Biomarker of ICS Effectiveness in Reducing Exacerbation Rates in COPD
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Blood eosinophils predict inhaled fluticasone response in bronchiectasis
Source: Eur Respir J, 56 (2) 2000453; 10.1183/13993003.00453-2020
Year: 2020
LATE-BREAKING ABSTRACT: Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in COPD?
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis
Source: Eur Respir J, 56 (3) 2002210; 10.1183/13993003.02210-2020
Year: 2020
Late Breaking Abstract - Effects of a new Airway Clearance Technology versus manual physiotherapy in COPD
Source: International Congress 2018 – Functional assessment of COPD
Year: 2018
Late Breaking Abstract - Blood and bronchoalveolar neutrophil signatures associate with COPD severity
Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases
Year: 2021
Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Late Breaking Abstract - Lack of stability of blood eosinophil counts in patients with COPD.
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase
Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations
Year: 2021
Late Breaking Abstract - Spatial response to small and large particle bronchodilator in subjects with asthma
Source: Virtual Congress 2021 – Hypoxia, exercise and respiratory function in pathophysiological conditions
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept